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Ea b s t r a c t
In this article, the full description of a heart failure with reduced
ejection fraction (HF_REF) cohort of 192 patients is provided.
Tables with the baseline demographic, prior history, ECG para-
meters, echocardiographic parameters, laboratory values and
pharmacological treatment of these patients are included. Also, the
quartile values of the analyzed circulating biomarkers: high sen-
sitivity Troponin T (hs-TnT), galectin-3 (Gal-3), C-terminal pro-
peptide of type I procollagen (CICP), soluble AXL (sAXL) and Brain
Natriuretic Peptide (BNP) are given. The main demographic and
clinical features of the patients’ subgroups that have hs-TnT, Gal-3,
CICP or BNP above the third quartile are described. Tables with
Pearson correlation analysis of the HF_REF patients’ biomarker
levels are included. And Pearson correlation analysis of the HF_REF
patients’ hs-TnT, Gal-3, CICP levels with patients’ biochemical
parameters, blood count and inﬂammation parameters are also
described. These data are related to the research articles (AXL
receptor tyrosine kinase is increased in patients with heart failure
(M. Batlle, P. Recarte-Pelz, E. Roig, M.A. Castel, M. Cardona, M.
Farrero, et al., 2014) [1] and Use of serum levels of high sensitivity
troponin T, galectin-3 and C-terminal propeptide of type I pro-
collagen at long term follow-up in Heart Failure patients with
reduced ejection fraction: comparison with soluble AXL and BNP
(M. Batlle, B. Campos, M. Farrero, M. Cardona, B. González, M.A.
Castel, et al., 2016) [2].
& 2016 Published by Elsevier Inc. This is an open access article
under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biomedicine
ore speciﬁc
subject areaCardiology, Heart Failureype of data Tables
ow data was
acquiredA visit in two specialized outpatient Heart Failure units as well as retrieval of
historical records. The circulating biomarker levels were quantiﬁed from serum
and plasma collected from the patients on the enrolment day.ata format Filtered, analyzed.
xperimental
factorsBlood samples from the HF patients were collected on from an antecubital vein. To
measure BNP levels, whole blood was collected in a chilled tube with the antic-
oagulant EDTA and was centrifuged at RCF 1800 g for 10 min at 4 °C. Serum
samples for hs-TnT, Gal-3, CICP and sAXL analysis were kept at room temperature
for at least 30 min after blood extraction and were later centrifuged at RCF 1800 g
for 10 min at room temperature. The supernatants were collected, aliquoted and
kept at 80 °C until analysis.xperimental
featuresThe ELISA assays used to quantify the circulating biomarkers’ levels were:
– the high sensitivity TnT assay (Troponin T high sensitive (05092744 119), Roche
Diagnostics)
– Galectin-3 Platinum ELISA (BMS279/2CE, eBioscience)
– the MicroValue CICP ELISA assay (8003, Siemens Diagnostics).
DD
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analyzer for BNP (Siemens Diagnostics).
– sAXL quantiﬁcation was devised in our laboratory using commercially available
antibodies.ata source
locationHospital Clinic and Hospital Sant Pau, Barcelona, Spain.ata accessibility The available data is with this articleValue of the data
 The data presented in this DIB article is important for interpretation of the circulating levels of
the biomarkers that we describe in our study.
 Heart failure is the end-stage of many heart diseases and its development can be highly variable
among patients.
 Many results from the literature are difﬁcult to compare due to heterogeneity of the heart failure
cohorts analyzed.
 The full description of the HF cohort patients and of the circulating biomarkers and their rela-
tionship with the clinical characteristics of the patients will provide deeper insight to the
researchers that work in the same ﬁeld and will allow more meaningful comparisons.1. Data
In this Data in Brief article, we provide the baseline demographic, prior history, ECG, echo-
cardiographic, laboratory and pharmacological parameters of 192 patients with heart failure and
reduced ejection fraction (Table 1). The distribution of the circulating values of ﬁve biomarkers and
their relationship with the patient´s clinical characteristics is also given Tables 2–6.2. Experimental design, materials and methods
2.1. Patient enrolment and collection of clinical data
A detailed description of subject enrollment and collection of clinical data has been reported
previously [1].2.2. Data analysis
Descriptive values are given as mean and standard error of the mean (SEM), or as frequencies (%)
or as quartile values. Correlation analysis among biomarkers and these with clinical laboratory values
were performed with Pearson correlation coefﬁcient. Statistical analysis was performed using the
SPSS software. Statistical signiﬁcance was indicated by P value o0.05. A detailed description data
analysis can be found elsewhere [1,2].
Table 1
Clinical characteristics of HF patients.
Parameter Mean7SEM or % n
Demographics
Age (years) 6271 192
Male (%) 85 164
Female (%) 15 28
Risk factors
Hypertension (%) 76 143
Dyslipidemia (%) 62 115
Diabetes mellitus (%) 35 66
Current/former smoker (%) 70 132
Previous AMI (%) 48 90
Etiology
Idiopathic (%) 28 53
Ischemic (%) 48 93
Valvular (%) 12 23
Hypertensive (%) 2.6 5
Other (%) 9.4 18
Clinical characteristics
NYHA FC II (%) 72 138
NYHA FC III-IV (%) 28 54
Body mass index (kg/m2) 28.170.4 183
Abdominal perimeter (cm) 103.071.1 158
Heart rate (beats/min) 7271 190
Systolic blood pressure (mmHg) 117.271.6 184
Diastolic blood pressure (mmHg) 72.070.9 183
Pulse pressure (mmHg) 45.571.4 183
6-min walk distance (m) 408.578.0 171
Symptoms and signs
Paroxysmal nocturnal dyspnea (%) 17 30
Reduction exercise tolerance (%) 44 74
Orthopnea (%) 29 51
Syncope (%) 13 23
Lower extremity edema (%) 14 24
Congestion signs (%) 10 10
Jugular venous distension (%) 12 12
Hepatojugular reﬂux (%) 19 18
ECG parameters
Sinusal rhythm (%) 59 110
Atrial ﬁbrillation (%) 9 17
Necrosis Q waves (%) 32 39
Intervent. Conduct. disorders (%) 63 105
Left bundle branch block (%) 23 26
Pacemaker (%) 55 106
Resynchronization therapy (%) 12 23
QRS length (ms) 134.772.8 180
Interval PR (ms) 168.973.4 123
Echocardiographic parameters
LVESD (mm) 53.670.9 167
LVEDD (mm) 67.470.7 181
LVEF (%) 27.370.5 192
LAD (mm) 48.270.7 173
IVST (mm) 10.470.1 180
LVPWT (mm) 10.070.1 174
LVH (%) 45 81
Laboratory values
Serum creatinine (mg/dL) 1.1870.03 189
GFR (mL/min) 56.670.7 178
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Table 1 (continued )
Parameter Mean7SEM or % n
Sodium (mEq/L) 139.870.2 190
Potassium (mEq/L) 4.670.04 188
Aspartate aminotransferase (UI/L) 26.171.4 182
Alanine aminotransferase (U/L) 27.572.3 188
Bilirubin (mg/dL) 0.8270.04 185
Uric acid (mg/dL) 6.9870.17 132
Glucose (mg/dL) 115.072.6 189
Total Cholesterol (mg/dL) 169.472.8 172
HDL Cholesterol (mg/dL) 40.770.7 167
LDL Cholesterol (mg/dL) 103.372.3 167
Triglycerides (mg/dL) 128.774.8 180
C Reactive Protein (mg/dL) 0.8870.19 143
Thyrotropin (mUI/L) 3.170.6 171
Thyroxine (ng/dL) 1.3170.02 150
Hemoglobin (g/L) 136.771.2 187
Hematocrit (L/L) 0.41970.003 189
Erythrocyte count (10E12/L) 4.5770.04 183
Lymphocytes count (10E9/L) 1.870.05 188
Platelet count (10E9/L) 218.274.6 184
Pharmacological treatment
ACEI (%) 68 125
ARB(%) 24 43
ACEI and/or ARB (%) 90 168
Beta-blocker (%) 94 176
Ca-antagonists (%) 8 15
Antithromb and/or anticoagul (%) 81 151
Statins (%) 62 116
Antidiabetics (%) 28 52
Diuretics (%) 79 146
Antialdosteronic agents (%) 55 102
Digoxin (%) 11 21
Antiarrhythmics (%) 22 41
Nitrates (%) 13 25
Hydralazine (%) 4 8
Anemia treatment (%) 4 8
NYHA FC (New York Heart Assotiation functional class), AMI (acute myocardial infarction), Intervent conduct disorders
(Interventricular conduction disorders), LVESD (left ventricle end-systolic diameter), LVEDD (left ventricle end-diastolic dia-
meter), LVEF (left ventricle ejection fraction), LAD (Left atrial diameter), IVST (Interventricular septum thickness), LVPWT (Left
ventricular posterior wall thickness), LVH (Left Ventricular Hypertrophy deﬁned as IVST Z11 mm),GFR (Glomerular ﬁltration
rate), ACEI (Angiotensin Converting Enzyme Inhibitor), ARB (Angiotensin Receptor Blocker), Antithromb and/or anticoagul
(Antithrombotic and/or anticoagulant).
Table 2











1st 11.0 4.9 68.6 69.1 76.2
2nd 17.4 5.8 85.6 82.4 167.7
3rd 28.7 7.5 112.3 98.1 362.7
High sensitivity Troponin T (hs-TnT), galectin-3 (Gal-3), C-terminal propeptide of type I procollagen (CICP), soluble AXL (sAXL)
and Brain Natriuretic Peptide (BNP).
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Table 4
Pearson correlation analysis of the HF_REF patients’ biomarker levels.
Number of pairs R coefﬁcient P value
Ln(hs-TnT) vs Ln(Gal-3) 189 0.25 o0.001
Ln(hs-TnT) vs Ln(CICP) 179 0.12 NS
Ln(hs-TnT) vs Ln(sAXL) 191 0.28 o0.0001
Ln(hs-TnT) vs Ln(BNP) 166 0.51 o0.0001
Ln(Gal-3) vs Ln(CICP) 178 0.044 NS
Ln(Gal-3) vs Ln(sAXL) 190 0.27 o0.001
Ln(Gal-3) vs Ln(BNP) 166 0.27 o0.001
Ln(CICP) vs Ln(sAXL) 180 0.17 o0.05
Ln(CICP) vs Ln(BNP) 157 0.26 0.001
Table 3
Proﬁles of HF patients that have a serum biomarker value above the third quartile value.
Characteristic 3Q_Hs-TnT 3Q_Gal-3 3Q_CICP 3Q_BNP
n 47 47 45 41
Age (years) 6271 6572 5872 6172
Sex (%M / %F) 89/11 79/21 80/20 88/12
Hypertension (%) 77 85 58 66
Diabetes mellitus (%) 38 47 27 27
Dyslipidemia (%) 60 57 51 46
Idiopathic etiology (%) 28 34 29 29
Ischemic etiology (%) 51 47 47 46
Valvular etiology (%) 13 11 11 12
Hypertensive etiology (%) 0 2 4 2
Other etiology (%) 8 6 9 10
NYHA FC II (%)/ FCIII_IV (%) 57/43 57/43 56/44 51/49
LVEF (%) 24.271.1 26.171.1 25.771.1 21.471.0
High sensitivity Troponin T (hs-TnT), galectin-3 (Gal-3), C-terminal propeptide of type I procollagen (CICP), soluble AXL (sAXL)
and Brain Natriuretic Peptide (BNP). New York Heart Association Funtional class II or III_IV (NYHA FC II FCIII_IV), left ventricular
ejection fraction (LVEF).
Table 5
Pearson correlation analysis of the HF_REF patients’ biomarker levels with patients’ biochemical parameters.
Laboratory values Ln(hs-TnT) Ln(Gal-3) Ln(CICP)
N R P N R P N R P
Serum creatinine(mg/dL) 188 0.43 o0.0001 187 0.34 o0.0001 177 0.15 o0.05
GFR (mL/min) 177 0.41 o0.0001 177 0.34 o0.0001 NS
Sodium (mEq/L) 189 0.24 o0.001 188 0.21 o0.01 NS
Potassium (mEq/L) NS NS NS
AST (IU/L) NS NS 170 0.18 o0.05
ALT (IU/L) NS NS NS
Total bilirubin (mg/dL) 184 0.22 o0.01 NS NS
Glucose (mg/dL) NS NS NS
Uric acid (mg/dL) 131 0.39 o0.0001 132 0.2 o0.05 NS
GFR (glomerular ﬁltration rate), AST (aspartate transaminase), ALT (alanine transaminase).
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Table 6
Pearson correlation analyses of the Ln of the biomarkers levels with patients’ blood count and inﬂammation parameters.
Laboratory values Ln(hs-TnT) Ln(Gal-3) Ln(CICP)




Platelet count (x109 /L) 183 0.22 o0.01 NS NS
Neutrophils (x109/L) 187 0.17 o0.05 NS NS
Lymphocytes (x109/L) 187 0.26 o0.001 NS NS
Monocytes (x109/L) NS NS NS
CRP (mg/dL) 142 0.24 o0.01 NS NS
Erythrocyte count
(x1012/L)
182 0.33 o0.0001 NS NS
Hemoglobin (g/dL) 186 0.31 o0.0001 NS NS
Hematocrit (L/L) 188 0.27 o0.001 NS NS
CRP (C-reactive protein).
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